Navigation Links
CEL-SCI Corporation Announces Elimination of $8.3 Million Convertible Notes
Date:9/2/2009

VIENNA, Va., Sept. 2 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM), a developer of vaccines for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today the elimination of Series K convertible notes (the "Notes"). The Notes, which had an initial principal value of $8.3 million, were issued in August 2006, and were convertible into common stock.

"The elimination of the Notes significantly strengthens the Company's balance sheet and removes a potential overhang for our shareholders," said Geert Kersten, CEL-SCI Corporation's Chief Executive Officer. "Over the past three months, we have considerably improved our financial condition, allowing us to move forward in the development of several of our promising clinical platforms."

About CEL-SCI Corporation

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R) which is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing a vaccine to prevent and treat swine and other influenzas using its L.E.A.P.S.(TM) technology platform and expects to soon finish the validation of its state-of-the-art facility in Maryland which it expects to utilize to launch aseptic filling for stem cell produced therapies and other biological products. The Company has operations in Vienna, Virginia, and Baltimore, Maryland.

For more information, please visit www.cel-sci.com.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2008. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CEL-SCI Completes $5.85 Million Registered Direct Offering
2. CEL-SCI Scientist Invited to Discuss Plans to Launch Unique Manufacturing Process That Saves Cost While Enhancing the Shelf Life of Drugs at 5th Annual Aseptic Processing of Sterile Drug Products Conference
3. CEL-SCI Expands Testing of Its Vaccine to Determine Efficacy Against More Virulent Strain of H1N1 Swine and Other Influenza Viruses
4. CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results
5. CEL-SCI Announces Exclusive Licensing Agreement for Cancer Drug Multikine(R) for Republic of South Africa
6. CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine
7. CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
8. CEL-SCI Corporation Reports Second Quarter 2008 Financial Results
9. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
10. CEL-SCI Corporation Releases Letter to Shareholders
11. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2017)... ... April 30, 2017 , ... ... the importance of substantially reducing melanoma and non-melanoma skin cancer through education by ... a collaboration between the American Academy of Dermatology and Pediatric Sun Protection Foundation, ...
(Date:4/30/2017)... Aliso Viejo, CA (PRWEB) , ... April 30, ... ... liquid animations created exclusively for use in Final Cut Pro X. Editors can ... bursts and more. Easily change the highlights, mid levels and shadows using simple ...
(Date:4/30/2017)... Louis, MO (PRWEB) , ... April 30, 2017 , ... ... a sharp increase in projected attendance for this year’s physician career fairs, with this ... , The complete schedule for the 2017 calendar year of national physician career fairs ...
(Date:4/30/2017)... , ... April 30, 2017 , ... San Francisco Dental ... to announce an updated blog post on the continual issue of the importance of ... seek a second opinion before dental surgery, but this can be a serious mistake. ...
(Date:4/29/2017)... ... April 29, 2017 , ... BECK ... launch of DonorBridge, its process and engagement analytics application built specifically for ... industry expertise with predictive analytics to help nonprofits operate more intelligently and ...
Breaking Medicine News(10 mins):
(Date:4/28/2017)... Inc. ("Hill-Rom") (NYSE: HRC ) today ... ended March 31, 2017, and raised its outlook ... guidance reflect the contribution from the Mortara Instrument ... 14, 2017.  For the fiscal second ... share compared to $0.33 per diluted share in ...
(Date:4/26/2017)... Phoenix Marketing Solutions ( Phoenix ) ... mission of transforming science into clinical practice. During a time ... innovative approach supports the life sciences industry by ... in science and medicine — which ultimately improves lives. ... 2002 by Tracy Doyle and Angela Fiordilino ...
(Date:4/25/2017)... Endo International plc (NASDAQ: ENDP ) will announce its ... management team will host a conference call and webcast before the ... The dial-in number to access the call is U.S./ Canada ... 6086379. Please dial in 10 minutes prior to the scheduled start ... call will be available from May 9, 2017 at 11:30 a.m. ...
Breaking Medicine Technology: